Moore Venture Partners

Moore Venture Partners (MVP) is a San Diego-area venture capital firm founded in 2010 and headquartered in Encinitas, California. The firm backs early, growth, and expansion-stage companies in technology and life sciences, with a particular emphasis on audacious founders building category-defining companies that can positively impact millions of lives. Core sectors include biotechnology, healthcare, and SaaS. Founder and Managing Partner Terry W. Moore brings more than 20 years of experience investing in, founding, leading, and advising technology, clean-tech, and life-sciences companies, and leads a lean team of two investment professionals consistent with the firm's measured investment pace of roughly one new investment per year. MVP has raised multiple fund vintages and is currently deploying its fourth fund, MVP IV, continuing to back life science and technology companies at all stages of growth. Individual check sizes can run up to USD 15 million, though formal fund size and AUM figures are not publicly disclosed. Across 29 disclosed portfolio companies the firm has produced one unicorn and two notable NASDAQ IPOs: Avidity Biosciences (NASDAQ IPO, June 2020, $636 million market cap at IPO), which advances antibody-siRNA complexes combining the modalities of ADCs and nucleic-acid therapeutics; and Savara Pharmaceuticals, which develops inhaled antibiotics for MRSA infection in cystic fibrosis. Portfolio sectors skew toward enterprise applications and life sciences. The most recent disclosed investment was a Series B in UCAP Power in February 2025. Moore Venture Partners takes a patient, high-conviction approach, committing deep operational and strategic support to each portfolio company rather than building a high-velocity fund. The firm's willingness to write checks from seed through late-stage Series C+ gives it the flexibility to follow founders through multiple rounds.